Skip to content

My Files [0]

These are the files you have added to your collection.

  • You don't have any documents yet, feel free to browse the website and add documents.

Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis

The Canadian Agency for Drugs and Technologies in Health (CADTH) conducted a review to evaluate the cost-effectiveness of Octaplas® against standard frozen plasma and its budgetary impact to the health system.


Please note, this is a revised version of the original CADTH health technology assessment published in March 2008 and amended in April 2009. Revisions were made to include more recent estimates of the risks of transfusions and corrected risk of Transfusion Related Acute Lung Injury (TRALI) per unit of fresh frozen plasma.